Drug Profile
Eramkafusp alfa - Assertio Therapeutics
Alternative Names: Anti-CD20 monoclonal antibody+IFN; IGN-002Latest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator ImmunGene
- Developer ImmunGene; The Leukemia & Lymphoma Society; Valor Biotherapeutics
- Class Antineoplastics; Immunotherapies; Interferons; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Interferon-alpha replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 23 Feb 2022 Spectrum Pharmaceuticals terminates a phase-I trial due to strategic reasons in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT02519270)
- 23 Feb 2022 Valor Biotherapeutics withdrew a phase II extension trial prior to enrolment due to strategic reasons in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT02847949)
- 05 Jan 2022 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV)